Get the latest Clearside Biomedical, Inc. (CLSD) stock news and headlines to help you in your trading and investing decisions. CLS-AX demonstrated intrinsic high potency, pan-VEGF inhibition through receptor blockade, prolonged duration observed in pharmacokinetic studies, and a pharmacodynamic effect in multiple animal models. Axitinib is a tyrosine kinase inhibitor (TKI) currently approved to treat renal cell cancer that achieves pan-VEGF blockade, directly inhibiting VEGF receptors-1, -2, and -3 with high potency and specificity. Supratemporal injection quadrant correlations were particularly consistent with previously reported anatomic variation by quadrant.Macular Edema associated with UveitisTitle: Variations in Intraocular Pressure Following Administration of Suprachoroidal Triamcinolone Acetonide Suspension (CLS-TA): Results from the Phase 3 PEACHTREE Clinical Trial for Uveitic Macular Edema Authors: Quan Dong Nguyen Conclusions: In the trial, the primary endpoint was met, with ~47% of patients gaining ≥15 Early Treatment Diabetic Retinopathy Study (ETDRS) letters. These statements may be identified by words such as “believe”, “expect”, “may”, “plan”, “potential”, “will”, and similar expressions, and are based on Clearside’s current beliefs and expectations. Patients with better visual acuity at presentation tend to be particularly vulnerable to vision loss.Title: Correlation of Best Corrected Visual Acuity and Central Subfield Thickness in Macular Edema Due to Retinal Vein Occlusion, Diabetic Retinopathy and Noninfectious Uveitis Authors: Michael Ip; Thomas A Ciulla Conclusions: There were moderate correlations between best corrected visual acuity (BCVA) and central subfield thickness (CST) in all diseases at baseline and for change at week 24. Mean change in visual acuity correlates with treatment intensity at one year. They also assigned press coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term. These forward-looking statements include statements regarding the development and potential benefits of CLS-AX, CLS-TA and the SCS Microinjector.
For more information, please visit www.clearsidebio.com.Cautionary Note Regarding Forward-Looking StatementsAny statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995.
Suprachoroidal injections showed consistency across demographics and ocular characteristics. Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that its second quarter 2020 financial results will be reported on Monday, August 10, 2020 after the close of the financial markets. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Clearside Biomedical, Inc. (CLSD) News – Find the latest company news headlines for Clearside Biomedical, Inc. and all the companies you research at NASDAQ.com Currency in USD Clearside believes this broad VEGF blockade may have efficacy advantages over existing retinal therapies by acting at a different level of the angiogenesis cascade, and may benefit patients who sub-optimally respond to current more narrowly focused anti-VEGF therapies. One indicator is far more accurate... but only a fraction of 1% of investors know about. Get short term trading ideas from the MarketBeat Idea Engine. The Company’s SCS injection platform is an inherently flexible, in-office, non-surgical procedure, intended to provide targeted delivery to the site of disease and to work with both established and new formulations of medications, as well as future therapeutic innovations such as gene therapy. News for Clearside Biomedical Clearside Biomedical.